SCHEDULE 13G/A: BlackRock Maintains Significant Stake in Repligen Corporation, Discloses 9.3% Beneficial Ownership
Beneficial Ownership Report Amendment
BlackRock, Inc. has filed an amendment to its Schedule 13G, reaffirming its beneficial ownership of 9.3% of Repligen Corporation's common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 5,198,107 shares of Repligen Corporation's common stock.
- This represents 9.3% of the total outstanding common shares of Repligen Corporation.
- BlackRock holds sole voting power over 5,044,499 shares and sole dispositive power over 5,198,107 shares.
- No shared voting or dispositive power was reported.
- The filing states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Repligen Corporation.
- BlackRock Fund Advisors, a subsidiary of BlackRock, Inc., is noted as beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual, routine disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Repligen Corporation.
Industry Context
This filing is a routine disclosure by a major institutional investor, BlackRock, Inc., regarding its passive ownership stake in Repligen Corporation, a company operating in the life sciences and biotechnology sector. Such filings are common for large asset managers who hold significant, but non-controlling, positions across various industries.
Stakeholder Impact
- Shareholders: The continued significant stake held by a major institutional investor like BlackRock may be viewed as a sign of confidence in Repligen Corporation, potentially reassuring other investors.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney issued by BlackRock, Inc. |
| 2025-03-31 | Date of event which requires the filing of this statement (reporting period end date). |
| 2025-04-24 | Date the Schedule 13G Amendment No. 4 was signed and filed. |
Keywords
BlackRock, Repligen Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Asset Management, Biotechnology, Life Sciences
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.